INSM
Insmed Incorporated
Biotechnology · Healthcare · United States
126.33
close · 2026-08-13
value
7
cheaper than peers7
quality
31
stronger fundamentals31
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 35.06× | 29 |
| price to book | 36.41× | 8 |
| forward P/E | 153.97× | 8 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 229.6% | 85 |
| operating margin | -65.5% | 51 |
| debt to equity | 105.3% | 24 |
| return on equity | -294.5% | 7 |
4 of 4 measures available
Facts
| market cap | $28B |
| free cash flow | -$606.2M |
| employees | 1,664 |
| first trade | 2000-06-01 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-06 |